Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this ongoing phase 3 study, ritlecitinib demonstrated sustained efficacy up to 24 months in patients aged 12 or older with alopecia areata, showing increased response rates with or without an initial loading dose and supporting its long-term use.

This study found that adding low-dose oral minoxidil to standard treatment for lichen planopilaris was safe but did not significantly improve hair density or thickness, although minor hair regrowth was observed in some scarring areas.

This phase II study found that gemcitabine plus paclitaxel showed promising activity and manageable toxicity as first-line therapy for recurrent or metastatic breast cancer, with a 35% overall response rate.

This case study reports the first known instance of isolated sub-acute cutaneous lupus erythematosus potentially induced by long-term nitrofurantoin therapy, with effective treatment using topical steroids and hydroxychloroquine.

This study found that combined therapy with cetirizine and topical steroids stabilized inflammation in most patients with lichen planus pilaris, though one patient experienced cardiac arrhythmia.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

This study found that nanostructured lipid carriers could serve as a promising vehicle for topical Acitretin delivery in psoriasis treatment, potentially reducing oral side effects and enhancing patient compliance.

In this study, copper-doxorubicin liposomes with multidose therapy reduced systemic toxicity compared to ammonium sulfate-loaded doxorubicin liposomes, while combinatorial strategies further enhanced tumor regression and accumulation.

This study found that systemic treatment with DS77754007, a KLK5 inhibitor, improved skin symptoms in a mouse model of Netherton Syndrome more effectively than certain antibody treatments, suggesting KLK5 inhibition as a promising therapeutic approach for this condition.

This study reports an improvement in lymphomatoid papulosis type A in a 52-year-old patient who concurrently used hormone-replacement therapy.

In this Italian retrospective study, ritlecitinib 50 mg/day showed effectiveness and good tolerability for treating severe alopecia areata over 24 weeks, achieving significant hair regrowth particularly in adolescents, as well as improvements in eyebrows, eyelashes, nails, and quality of life, with mostly mild adverse effects.

This study found that leflunomide combined with prednisone showed good efficacy and tolerance in treating lupus nephritis where cyclophosphamide was ineffective or intolerable.

In this study, researchers found that among adults with severe alopecia, continued treatment with baricitinib for 104 weeks maintained hair regrowth effectively in those who responded at 52 weeks, with improved outcomes noted in some initially non-responders receiving 4 mg.

This case report describes a probable connection between lamotrigine treatment and hair loss, resolving upon discontinuation, suggesting alopecia as a rare side effect of the drug.

In this study, baricitinib treatment over an average of 18.5 months resulted in a 72% reduction in alopecia severity scores among patients aged 65 or older, with mild adverse effects and no severe complications reported.

In this study, the safety profiles of four treatments for early rheumatoid arthritis were assessed over one year, and the most serious side effects necessitating treatment discontinuation were noted in the leflunomide group, whereas no such withdrawals occurred in the methotrexate plus prednisolone group.

This study found that MK-5108 is well tolerated at high doses as monotherapy in cancer patients, showing stable disease and some antitumor activity, particularly in combination with docetaxel.

This case report observed successful hair regrowth with ritlecitinib in a patient with severe alopecia who did not respond to a previous year of baricitinib therapy.

This case report describes the first successful use of telitacicept in treating a patient with systemic lupus erythematosus and a history of papillary thyroid carcinoma, suggesting its potential as a therapeutic option for such conditions.

This audit of ritlecitinib prescribing for severe alopecia areata found that regional practices largely followed national guidelines but highlighted the need for better psychological assessments and more consistent use of SALT scoring to inform treatment continuation decisions after 36 weeks.

This review describes the approved use and adverse effects of gefitinib in patients with advanced non-small cell lung cancer, without presenting new clinical findings.

This study found that approximately 85% of adults with severe alopecia areata who responded to baricitinib at 52 weeks maintained their improvement over a span of four years.

This study found that tofacitinib significantly improved disease activity in most patients with LPP, though further research is needed to refine protocols, understand response predictors, and address gender-specific adverse effects.

This report describes a 7-year-old girl with monilethrix who showed significant improvement while on acitretin treatment, but symptoms returned after stopping the medication.

Telitacicept effectively improved hair regrowth in a woman with lupus and alopecia.

This study reported that Sintilimab combined with chemotherapy may improve outcomes in advanced NSCLC patients but carries a higher risk of certain side effects, including hypothyroidism.

This article reviews 12 newly approved drugs with pediatric indications from 2001, discussing their clinical importance for general pediatricians, but reports no new clinical results.

In this study, researchers developed isotretinoin-loaded Delonix polymeric nanoparticles that target hair follicles and found they effectively sustained drug release, reduced IL-6 production in vitro without inhibiting P. acnes, and may prevent isotretinoin-related skin irritation in vivo in Wistar rats.